New Edge Advisors, LLC Lineage Cell Therapeutics, Inc. Transaction History
New Edge Advisors, LLC
- $20.5 Billion
- Q3 2025
A detailed history of New Edge Advisors, LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 11,500 shares of LCTX stock, worth $21,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,500Holding current value
$21,850% of portfolio
0.0%Shares
4 transactions
Others Institutions Holding LCTX
# of Institutions
131Shares Held
103MCall Options Held
251KPut Options Held
50K-
Broadwood Capital Inc New York, NY49.6MShares$94.2 Million5.18% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$18.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.01MShares$17.1 Million0.0% of portfolio
-
Defender Capital, Llc.6.83MShares$13 Million3.7% of portfolio
-
Raffles Associates LP New York, NY5.39MShares$10.2 Million10.91% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $323M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...